KLP Kapitalforvaltning AS Purchases Shares of 16,100 CRISPR Therapeutics AG (NASDAQ:CRSP)

KLP Kapitalforvaltning AS acquired a new stake in CRISPR Therapeutics AG (NASDAQ:CRSP) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 16,100 shares of the company’s stock, valued at approximately $634,000.

A number of other hedge funds have also recently made changes to their positions in CRSP. Highline Wealth Partners LLC bought a new stake in CRISPR Therapeutics during the fourth quarter worth $39,000. Western Pacific Wealth Management LP grew its stake in shares of CRISPR Therapeutics by 100.0% in the 4th quarter. Western Pacific Wealth Management LP now owns 1,000 shares of the company’s stock worth $39,000 after acquiring an additional 500 shares in the last quarter. Wilmington Savings Fund Society FSB purchased a new stake in shares of CRISPR Therapeutics in the third quarter valued at about $40,000. Spire Wealth Management lifted its position in shares of CRISPR Therapeutics by 303.7% during the fourth quarter. Spire Wealth Management now owns 1,970 shares of the company’s stock valued at $78,000 after purchasing an additional 1,482 shares in the last quarter. Finally, MCF Advisors LLC purchased a new position in CRISPR Therapeutics during the fourth quarter worth about $80,000. 69.20% of the stock is currently owned by institutional investors and hedge funds.

CRISPR Therapeutics Price Performance

CRSP opened at $34.19 on Thursday. CRISPR Therapeutics AG has a one year low of $32.51 and a one year high of $67.88. The firm has a market capitalization of $2.93 billion, a P/E ratio of -7.82 and a beta of 1.85. The company has a fifty day moving average price of $42.60 and a 200-day moving average price of $44.90.

CRISPR Therapeutics (NASDAQ:CRSP) last released its quarterly earnings results on Tuesday, February 11th. The company reported ($0.44) earnings per share for the quarter, beating the consensus estimate of ($1.15) by $0.71. CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. On average, analysts expect that CRISPR Therapeutics AG will post -5.16 earnings per share for the current year.

Insider Activity at CRISPR Therapeutics

In other news, General Counsel James R. Kasinger sold 2,850 shares of the stock in a transaction dated Tuesday, March 11th. The stock was sold at an average price of $42.42, for a total transaction of $120,897.00. Following the transaction, the general counsel now directly owns 77,530 shares in the company, valued at approximately $3,288,822.60. This represents a 3.55 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Samarth Kulkarni sold 18,360 shares of the business’s stock in a transaction that occurred on Wednesday, February 19th. The stock was sold at an average price of $55.20, for a total value of $1,013,472.00. Following the completion of the sale, the chief executive officer now owns 171,613 shares of the company’s stock, valued at $9,473,037.60. The trade was a 9.66 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 32,381 shares of company stock valued at $1,608,243 over the last three months. 4.10% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on the company. Bank of America cut their target price on CRISPR Therapeutics from $98.00 to $85.00 and set a “buy” rating on the stock in a research note on Tuesday, January 7th. Royal Bank of Canada reduced their price objective on CRISPR Therapeutics from $53.00 to $48.00 and set a “sector perform” rating for the company in a research note on Wednesday, February 12th. HC Wainwright reiterated a “buy” rating and set a $65.00 target price on shares of CRISPR Therapeutics in a research note on Thursday, February 13th. Citigroup reduced their price target on shares of CRISPR Therapeutics from $89.00 to $82.00 and set a “buy” rating for the company in a research report on Tuesday, February 18th. Finally, Chardan Capital lowered their price objective on shares of CRISPR Therapeutics from $94.00 to $84.00 and set a “buy” rating on the stock in a research report on Thursday, February 13th. Two research analysts have rated the stock with a sell rating, nine have assigned a hold rating and eleven have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $73.11.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.